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Abstract
We describe a case of suspected COVID-19 pneumonia in a 61-year-old male with known
primary central nervous system diffuse large B-cell lymphoma (DLBCL) who underwent
restaging PET/CT during the initial peak of infection of COVID-19 pneumonia within the New
York region. At the time of his routine PET-CT to assess for disease progression, typical CT
imaging features of COVID-19 pneumonia were identified. Upon further investigation, the
patient was asymptomatic, and his infection status remained unknown.
He was subsequently lost to follow-up with his COVID-19 status pending.
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Introduction
Coronavirus disease of 2019 (COVID-19) is a novel coronavirdae virus which causes severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 predominantly manifests
as an atypical pneumonia features by nonproductive cough, chest pain, shortness of breath,
fever and malaise. The outbreak originated in Wuhan Provence of China, and has now spread to
much of the globe, infecting over 16.5 million people worldwide [1]. The United States to date
have approximately 4.4 million confirmed cases and nearly 150,000 deaths.
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COVID-19 causes an atypical pneumonia that can be diagnosed by chest radiograph or chest CT
imaging. Both modalities illustrate multifocal bibasilar predominant patchy airspace opacities
that may progress to confluent consolidations in later stages [2-3]. As these airspace opacities
evolve, progressive atypical respiratory system distress ensues, with the resulting hypoxemia
causing a cataclysmic cascade of multiorgan distress and eventual multiorgan failure in some
patients [4-6]. This end stage severe inflammatory response has been categorized as cytokine
storm syndrome (CSS). This multi-organ inflammatory process seems to be triggered by the
massive intravascular release of pro-inflammatory cytokines such as interleukin-6 (IL-6) into
the bloodstream, contributing to prevalence of diffuse endovascular injury, with significant
microthrombi burden reported on autopsy series [7-9].
This diffuse microthrombi burden combined with endothelial destabilization results in a severe
multifocal inflammatory response, noted by the histological presence of megakaryocytes,
platelets, fibrin, neutrophils and other inflammatory cells [9]. As the viral particles enter the
cells, primarily through the angiotensin converting enzyme ACE2 receptor [10], viral replication
begins to overwhelm the cellular structure, inciting a pro-inflammatory state that disrupts the
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infected and adjacent endothelium. Similar histopathological findings were noted in the SARS
outbreak in Southeast Asia during 2003, which was attributed to a related virus of the
coronavirdae family [4]. To date, COVID-19 infection predominantly affects the respiratory
system; however, various organ systems have been impacted such as the central nervous system
(CNS), kidneys and heart, likely as a sequala of severe inflammation in the setting of
microthrombi disease [7,11-12].
It is well known that fluorodeoxyglucose (FDG) positron emission tomography-computed
tomography (PET-CT) imaging demonstrates increased uptake across a variety of pathological
etiologies including infections, inflammatory processes, and neoplasms. For example, FDG
PET-CT imaging has been demonstrated to be useful in localizing foci of infection and
inflammation in patients with fever of unknown origin [13]. In cases of COVID-19 infection
documented on whole-body PET/CT, interstitial pneumonia is the predominant imaging
manifestation, with multifocal bibasilar predominant ground glass opacities demonstrating
increased FDG uptake in the lung parenchyma [14-15]. The increased FDG uptake is
nonspecific, however the etiology remains primarily infectious/inflammatory rather neoplastic.

Case Presentation
A 61-year-old male with a history of primary diffuse large B-cell lymphoma (DLBCL) of the CNS
was treated by high dose BEAM conditioning chemotherapy followed by autologous
hematopoietic stem-cell transplantation. A restaging top of head to mid-thigh FDG PET-CT
was performed on March 30th, 2020. The study was performed in an outpatient imaging center
within the New York region during a time of high prevalence of COVID-19 infection.
As an incidental finding, the lung parenchyma on CT demonstrated interval development of
multifocal, bibasilar and peripheral predominant, ground-glass opacities with areas of
reticulation within the upper lobes demonstrating prominent FDG uptake (Figures 1-3). The
patient however remained asymptomatic. Given the current high prevalence of COVID-19
within the New York region, early interstitial pneumonia related to underlying severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was given a high consideration.
The patient’s COVID-19 testing status remained unknown and he was subsequently lost to
follow-up.
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FIGURE 1: Selected axial CT and PET-CT fusion images.
Selected axial CT and PET-CT fusion images demonstrate multiple, predominantly peripheral
ground-glass opacities within the left upper lobe (arrow) with more subtle ground glass opacities in
the right upper lobe with increased fluorodeoxyglucose (FDG) uptake (arrow).
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FIGURE 2: Selected axial CT and axial PET-CT fusion images.
Selected axial CT and axial PET-CT fusion images through the mid chest level in lung windows
demonstrate a peripheral, rounded ground-glass opacity with reticular characteristics and an air
bronchogram in the left upper lung lobe (wide arrow). In the right upper lobe, a reticular ground
glass opacity is also seen (thin arrow). The lesions also demonstrated increased
fluorodeoxyglucose (FDG) uptake measuring up to standardized uptake value (SUV) 6.7.
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FIGURE 3: Axial CT and PET-CT fusion images.
Axial CT and PET-CT fusion images show an enlarged hypermetabolic lymph node within the
mesenteric region of the pelvis (wide arrow) with standardized uptake value (SUV) 6.8 which
represents recurrent lymphoma.

Discussion
Typical findings of COVID-19 pneumonia include multilobar, bilateral ground glass opacities
with or without consolidation [2-3]. These most commonly occur in the posterior or peripheral
lungs. The ground glass opacities typically have a rounded or reverse halo morphology. Other
lung findings include a reticular pattern representing thickened interstitial structures isolated
or superimposed on ground glass opacities, air bronchograms, bronchiectasis, and pleural
thickening. Atypical findings of COVID-19 pneumonia are isolated and/or segmental
consolidations, nodules, lung cavitation and pleural effusions would suggest alternative
diagnoses.
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Various risk factors have been identified in predictors of morbidity and mortality for those with
COVID-19 infection including advanced age, obesity, preexisting cardiovascular or
cerebrovascular diseases, as well as underlying immunosuppression, including in the setting of
malignancy and oncologic therapeutics [16]. Given that whole body FDG PET-CTs are largely
obtained for cancer follow-up and restaging purposes, this patient population is at significantly
higher risk of morbidity and mortality in the setting of SARS-CoV-2 infection.
Furthermore, according to a recent report by Albano et al., six of 65 (9%) patients undergoing
restaging PET/CT for various malignancy demonstrated incidental interstitial pneumonia on
CT with corresponding FDG uptake, suggesting SARS-CoV-2 infection may not be infrequent
even in asymptomatic patients [14]. In addition, similar findings have been reported on PET-CT
in COVID-19 patients displaying FDG-avid ground glass opacities, including some reported
cases of FDG-avid mediastinal lymph nodes without significant nodal enlargement [14-15].
Moreover, the false negative rate of reverse transcriptase polymerase chain reaction (PCR)based SARS-CoV-2 screening and testing in early asymptomatic infection, particularly in the
time frame of March 2020, was a striking 38% according to a recent study by Kucirka et al.
published in Annals of Internal Medicine in May 2020 [17]. Many of the typical radiological
findings of early COVID-19 interstitial pneumonia are well-illustrated in our patient.
Additionally, there is noteworthy increased FDG uptake within the affected parts of the lung
demonstrating findings classically described in the setting SARS-CoV-2 mediated pneumonia
(Figures 1, 2). Although the testing status of our patient remains unknown, it is highly
suggestive that our patient was indeed infected with the novel coronavirus of 2019, especially
giving his baseline immunocompromised state making him a high-risk and susceptible patient
meeting CDC guidelines for an early asymptomatic person under investigation (PUI) for
COVID-19 pneumonia [18].
Therefore, in regions of high prevalence of COVID-19, several considerations should be made
by nuclear medicine staff for oncologic patients undergoing restaging PET/CT scans in order to
minimize potential exposure to COVID-19 of this extremely vulnerable patient population [1920]. Screening should be performed as a significant portion of the population may be
asymptomatic as highlighted in the case presented here. Additionally, all equipment should be
properly disinfected after scans including the computers, imaging gantry, desks and tables.
Nuclear medicine staff should also have access to adequate personal protective equipments
(PPEs) to protect themselves and to decrease transmission risk to vulnerable patients.

Conclusions
We describe a case of suspected COVID-19 pneumonia in a 61-year-old male with primary
DLBCL of the central nervous system who underwent routine restaging PET-CT during the
initial peak of COVID-19 infection in the New York region.
The patient demonstrated classic imaging findings of early interstitial pneumonia on PET/CT,
meeting radiologic diagnostic criteria of SARS-Cov-2 infection on chest imaging. Therefore,
taking into consideration the ongoing high prevalence of COVID-19 in the New York region
and the patient’s underlying immunocompromised state, early interstitial pneumonia related to
underlying SARS-CoV-2 infection was given a high consideration. Although our patient lacked
a confirmatory positive PCR result, these typical imaging features should be kept in mind when
imaging oncologic patients at high risk for COVID-19 exposure.
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